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Introduction: Cystic ﬁbrosis (CF) is a genetic disease caused by mutations in
the CF transmembrane conductance regulator (CFTR). Defective membrane mutant
CFTR (DF508) expression is instrumental in mediating lung inﬂammation. Lung
stromal and inﬂammatory cells secrete serine-proteases which have well described
deleterious effects on the integrity of lung tissue. However, the effect of proteases on
CFTR has not yet been addressed. The aim of the present study was to characterize
the effect of tissue (trypsin-4) and neutrophil-derived (Elastase or NE) serine-
proteases on CFTR both at structural and functional levels.
Results: We show here in bronchial and alveolar epithelial cells that NE and
trypsin-4 up-regulate IL-8 production 1.3 to 1.5 fold in CF cells (over-expressing
DF508 CFTR), respectively, when compared to WT cells. This induced IL-8
up-regulation was correlated with the NE (but not trypsin-4) generation of a
cleaved 95 kDa CFTR molecular species, suggesting that the IL-8 pro-inﬂammatory
phenotype is exacerbated by CFTR degradation.
In WT CFTR-transfected Xenopus oocytes, Forskolin+IBMX enhanced the slope
of linear shaped I/V curves, consistent with the functional expression of CFTR.
In WT CFTR-oocytes also incubated with NE, increase in conductance was 2 to
2.5 fold lower.
Conclusions: We demonstrate here that while both serine-proteases NE and
trypsin-4 up-regulate IL-8 in bronchial and alveolar epithelial cells, only NE is
able to signiﬁcantly degrade the WT CFTR protein. This degradation also occurred
with DF508 CFTR, suggesting that NE may exacerbate the CFTR phenotype in CF.
We are currently dissecting the mechanisms involved.
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The pathogenesis of lung disease in cystic ﬁbrosis (CF) has not been fully
elucidated; however, neutrophil-dominated inﬂammation is thought to play a major
role. Nonetheless, a number of proteases produced by other cells in the lung may
also play a pivotal role in CF lung damage. Human lysosomal cysteine proteases
are a family of proteases that have been relatively unexplored in the area of CF
lung disease. We have shown that cathepsin S activity is increased in CF BAL ﬂuid,
compared with that from healthy individuals. In addition to lung tissue degradation,
cathepsins have been found to contribute signiﬁcantly to the destruction of host
defence proteins such as SLPI, b-defensins and lactoferrin. These ﬁndings indicate
a role for cathepsin S in the diminution of the lung antiprotease and antimicrobial
screen possibly leading to lung destruction and favouring conditions for bacterial
infection. We have identiﬁed epithelial cells as a source of cathepsin S in the
CF lung, with the demonstration that CF bronchial and tracheal epithelial cell
lines (CFBE41o− and CFTE29o−) secrete signiﬁcantly more active cathepsin S
than normal cells (16HBE14o− and 9HTEo−) in the absence of proinﬂammatory
stimulation. On the basis of our results to date, we postulate that upregulated
cathepsin S plays an important role in CF lung disease and we are currently
investigating reasons for this upregulation of cathepsin S in CF epithelial cells.
This data will shed valuable light on the role of cathepsin S in CF, an area that has
been overshadowed to date, and may open up new avenues for exploration in the
search for an effective therapeutic target in CF lung disease.
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Increased airway Na+ absorption and airway surface liquid (ASL) depletion cause
airway mucus obstruction, chronic airway inﬂammation and emphysema, which
are the main characteristics of cystic ﬁbrosis (CF)-like lung disease in bENaC-
overexpressing (bENaC-Tg) mice. The aim of this study was to investigate the mech-
anism underlying emphysema formation in this murine model of CF lung disease.
Screening of mRNA levels of proteases/antiproteases in the lungs of bENaC-Tg
mice compared to wild-type littermates showed a marked increase of macrophage
elastase (also known as MMP12) transcript expression. By performing longitudinal
measurements of lung volumes and mean linear intercepts, we demonstrated that
the onset of emphysema formation occurred in the ﬁrst days of life and that distal
airspace enlargement progressed in older bENaC-Tg mice. To elucidate the role of
MMP12 in emphysema formation, we crossed bENaC-Tg with MMP12 deﬁcient
mice and found that double-mutant bENaC-Tg/MMP12−/− were protected from
emphysema formation. Further, daily treatment with the MMP inhibitor GM 6001
prevented emphysema formation in bENaC-Tg mice. Our results indicate that ASL
depletion leads to macrophage activation and elevated secretion of MMP12 and
identify MMP12 as cause of emphysema in bENaC-Tg mice. These results may
offer novel therapeutic opportunities for the treatment of CF lung disease.
Supported by EC (MEXT-CT-2004–013666).
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Epithelial-derived endogenous antimicrobial molecules such as defensins or
trappin-2 (T2) have the potential to affect the phenotype of phagocytic myeloid
cells (macrophages, neutrophils, dendritic cells), by modifying their differentiation,
chemotactic properties and activation in different lung pathologies. Recently, it has
been shown that T2 can improve the clearance of Pseudomonas aeruginosa (P.a) by
alveolar macrophages (AM) (Wilkinson et al. Am. J. Pathol, 2009, 174:1338−46).
The aim of the present study is to study T2 opsonizing effect on the clearance of
P.a by AM and a potential modulation on cytokine productions by AM and lung
epithelial cells stimulated with P.a.
We have measured the early clearance of PAK (a wild-type P.a. strain), PAKDﬂiC
(a ﬂagellum-deﬁcient PAK) or PAKL88 (a PAK strain with a TLR5-binding site-
deﬁcient ﬂagellum), pre-incubated or not with T2 (100 nM, a sub-lytic concentra-
tion), by murine AM (MH-S cell line). We conﬁrm that T2 enhances the early
clearance of PAK by AM but not that of PAKDﬂiC or PAKL88. In addition,
T2-pre-incubated PAK but not PAKDﬂiC increases AM or lung epithelial cells
TNF-a and IL-8 secretions. Moreover, epithelial cells stimulated with PAK-ﬂagellin
pre-incubated with T2 secreted higher levels of IL-8, when compared with cells
incubated with ﬂagellin alone.
Our data suggest that T2, by ‘opsonising’ P.a and by increasing cytokine production
of AM or lung epithelial cells may constitute an important modulator of innate
immune responses. Moreover, T2 activity requires P.a ﬂagellin-TLR5 interaction.
We are currently assessing whether T2 could improve the defective bacterial
clearance observed in cystic ﬁbrosis.
